Sullivan Bruyette Speros & Blaney LLC Buys 42 Shares of Amgen Inc. (AMGN)
Sullivan Bruyette Speros & Blaney LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,023 shares of the medical research company’s stock after purchasing an additional 42 shares during the period. Sullivan Bruyette Speros & Blaney LLC’s holdings in Amgen were worth $1,209,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of AMGN. PGGM Investments lifted its holdings in Amgen by 2.3% in the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock valued at $115,555,000 after acquiring an additional 15,059 shares during the last quarter. Shelton Capital Management raised its position in Amgen by 82.7% in the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock valued at $17,883,000 after purchasing an additional 49,354 shares during the period. Greylin Investment Mangement Inc. raised its position in Amgen by 466.9% in the second quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock valued at $2,416,000 after purchasing an additional 11,555 shares during the period. Kelman Lazarov Inc. raised its position in Amgen by 8.2% in the second quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 120 shares during the period. Finally, Osborne Partners Capital Management LLC raised its position in Amgen by 0.5% in the second quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock valued at $2,932,000 after purchasing an additional 91 shares during the period. Institutional investors and hedge funds own 78.20% of the company’s stock.
A number of analysts have issued reports on AMGN shares. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $199.00 target price on the stock in a research report on Friday, October 27th. Bank of America Corporation boosted their target price on Amgen to $210.00 and gave the company a “buy” rating in a research report on Thursday, October 5th. Barclays PLC boosted their target price on Amgen from $180.00 to $190.00 and gave the company an “equal weight” rating in a research report on Friday, October 13th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $203.00 target price on shares of Amgen in a research report on Thursday, September 7th. Finally, Royal Bank Of Canada started coverage on Amgen in a research report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price objective on the stock. Thirteen investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $190.03.
Amgen Inc. (AMGN) opened at $170.77 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. Amgen Inc. has a 12 month low of $138.83 and a 12 month high of $191.10. The firm has a market cap of $122,954.73, a P/E ratio of 13.46, a PEG ratio of 2.45 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion during the quarter, compared to analysts’ expectations of $5.75 billion. During the same period last year, the company posted $3.02 EPS. The company’s revenue was down .7% on a year-over-year basis. research analysts predict that Amgen Inc. will post 12.66 earnings per share for the current year.
Amgen announced that its Board of Directors has initiated a share buyback program on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be paid a dividend of $1.15 per share. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.69%. Amgen’s dividend payout ratio (DPR) is 41.63%.
In related news, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $171.58, for a total transaction of $261,659.50. Following the sale, the executive vice president now owns 57,631 shares in the company, valued at approximately $9,888,326.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,050 shares of company stock valued at $1,239,673. Corporate insiders own 0.19% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.